高盛研报:重症肌无力市场格局重塑?强烈看好再鼎医药艾加莫德绝对竞争力

智通财经网
16 Apr

近日闭幕的神经领域年度盛会美国神经病学会(AAN)年会上,众多神经领域前沿进展惊艳亮相,其中重症肌无力(MG)的研究进展更是硕果累累。多款新型靶向生物制剂公布了最新临床研究结果,不仅推动MG治疗进入分子免疫时代,也预示着MG治疗药物竞争格局的改变。智通财经APP获悉,4月14日,国际投行高盛发布了一份深度研究报告,重点聚焦了这一疾病领域的最新进展。报告中高盛详细分析了再鼎医药(09688)的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10